Device Trial Radar · NCT06464016
Complications in Pediatric Mechanical Circulatory Assistance: Evaluation of Infection Management.
Last checked: Nov 20, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
47
Planned (sponsor's estimate)
Start
Jul 4, 2023
Primary completion
Oct 1, 2025
Study completion Nov 1, 2025
Sponsor
- Lead sponsor
- Claude Bernard UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hospices Civils de Lyon
- First posted
- Jun 18, 2024
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 1 day, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Heart failure is a major cause of mortality and morbidity in children. Heart transplantation can significantly improve the prognosis of patients with severe heart failure, but access is limited by a shortage of transplants. Long-term mechanical circulatory support is a major advance in the management of heart failure and can provide haemodynamic support while awaiting myocardial recovery or heart transplantation. The Berlin Heart (BH) EXCOR is the only long-term support system available for children. Despite technical and medical advances in circulatory support, infection is a common complication and a major cause of morbidity and mortality in patients on BH. There are few studies on the management of infection with mechanical support. Current ISHLT (International Society for Heart and Lung Transplantation) recommendations are based on expert opinion and observational studies. Some experts recommend anti-infective therapy until transplantation for specific support infections or for support-associated infections with persistent bacteraemia.
Conditions
- Heart-Assist Devices
- Infections
- Heart Transplant Infection
Interventions
Ventricular Assist Device with Berlin Heart EXCORDevice
The Berlin Heart® EXCOR is a type of "artificial heart" pump that pulls blood from the ventricle and then sends that blood to the aorta or pulmonary trunc, thereby taking away extra work from the native heart. The device, which comes in several sizes, is not totally implanted inside the body.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relapse of VAD-infection after discontinuation of anti-infective therapyTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospices Civils de Lyon
Lyon, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.